Vistagen Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed Jun 15, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 15, 2026
VTGN$0.18+12.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share amounts)
| Common Stock · AdditionalPaid-inCapital · TreasuryStock · AccumulatedOther Comprehensive Income (Loss) · AccumulatedDeficit · TotalStockholders’Equity | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||||||
| Balance at March 31, 2024 | 27,029,731 | $27 | $474,441 | $(3,968) | $— | $(356,214) | $114,286 | ||||||||
| Stock-based compensation expense | — | — | 4,315 | — | — | — | 4,315 | ||||||||
| Sale of common stock pursuant to 2019 Employee Stock Purchase Plan | 74,804 | — | 201 | — | — | — | 201 | ||||||||
| Issuance of common stock under Open Market Sale Agreement, net of issuance costs | 1,108,587 | 1 | 2,999 | — | — | — | 3,000 | ||||||||
| Issuance of common stock upon exercise of Pre-Funded Warrants | 788,359 | 1 | — | — | — | — | 1 | ||||||||
| Net loss | — | — | — | — | — | (51,418) | (51,418) | ||||||||
| Balance at March 31, 2025 | 29,001,481 | 29 | 481,956 | (3,968) | 5 | (407,632) | 70,390 | ||||||||
| Stock-based compensation expense | — | — | 3,997 | — | — | — | 3,997 | ||||||||
| Sale of common stock pursuant to 2019 Employee Stock Purchase Plan | 217,784 | — | 231 | — | — | — | 231 | ||||||||
| Unrealized loss on marketable securities available-for-sale, net | — | — | — | — | (7) | — | (7) | ||||||||
| Issuance of common stock under Open Market Sale Agreement, net of issuance costs | 10,403,244 | 11 | 30,575 | — | — | — | 30,586 | ||||||||
| Issuance of common stock upon exercise of stock options | 2,330 | — | 8 | — | — | — | 8 | ||||||||
| Net loss | — | — | — | — | — | (69,685) | (69,685) | ||||||||
| Balance at March 31, 2026 | 39,624,839 | $40 | $516,767 | $(3,968) | $(2) | $(477,317) | $35,520 | ||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.